Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility

L. Silvia Munoz-Price, Allison E. Reeme, Blake W. Buchan, Roberta T. Mettus, Mustapha M. Mustapha, Daria Van Tyne, Ryan K. Shields, Yohei Doid

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

We report patient-to-patient transmission of Enterobacter hormaechei isolates with reduced susceptibility to ceftazidime-avibactam due to production of KPC-40, a variant of KPC-3 with a two-amino-acid insertion in the Ώ-loop region (L167_E168dup). The index patient had received a prolonged course of ceftazidime-avibactam therapy, whereas the second patient had not received the agent and still became colonized with the KPC-40-producing strain. The complex dynamics of KPC (Klebsiella pneumoniae carbapenemase) described here highlight several key diagnostic and therapeutic considerations.

Original languageEnglish
Article numbere00955-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number10
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility'. Together they form a unique fingerprint.

Cite this